NYSE:FMS - Fresenius Medical Care AG & Co. KGaA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $45.13
  • Forecasted Upside: 8.45 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 10 Buy Ratings
  • 1 Strong Buy Ratings
$41.61
▼ -0.5 (-1.19%)
1 month | 3 months | 12 months
Get New Fresenius Medical Care AG & Co. KGaA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FMS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$45.13
▲ +8.45% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Fresenius Medical Care AG & Co. KGaA in the last 3 months. The average price target is $45.13, with a high forecast of $48.00 and a low forecast of $42.00. The average price target represents a 8.45% upside from the last price of $41.61.
Buy
The current consensus among 14 polled investment analysts is to buy stock in Fresenius Medical Care AG & Co. KGaA. This rating has held steady since April 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/12/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
3/8/2020
  • 1 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/6/2020
  • 1 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/4/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/3/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/3/2020

Latest Recommendations

  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/19/2020Royal Bank of CanadaReiterated RatingNeutralLow
i
11/10/2020Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
i
11/5/2020UBS GroupReiterated RatingBuyLow
i
11/4/2020Nord/LBUpgradeHold ➝ BuyLow
i
10/30/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
i
10/30/2020Morgan StanleyReiterated RatingEqual WeightLow
i
10/13/2020Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
i
9/3/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
i
8/18/2020Morgan StanleyReiterated RatingEqual WeightLow
i
8/13/2020Royal Bank of CanadaReiterated RatingNeutralLow
i
8/5/2020Jefferies Financial GroupDowngradeBuy ➝ HoldLow
i
8/3/2020DZ BankReiterated RatingBuyLow
i
7/28/2020Berenberg BankReiterated RatingBuyLow
i
7/17/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
i
6/1/2020BarclaysReiterated RatingOverweightLow
i
5/21/2020SunTrust BanksBoost Price TargetBuy$46.00 ➝ $48.00Low
i
5/20/2020Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
i
5/19/2020JPMorgan Chase & Co.Reiterated RatingOverweightHigh
i
5/14/2020Kepler Capital MarketsUpgradeHold ➝ BuyLow
i
5/11/2020SunTrust BanksBoost Price TargetBuy$42.00 ➝ $46.00Low
i
5/7/2020DZ BankReiterated RatingBuyLow
i
4/27/2020BarclaysReiterated RatingOverweightMedium
i
4/20/2020Royal Bank of CanadaReiterated RatingHold$42.00Low
i
4/17/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyLow
i
4/13/2020SunTrust BanksLower Price TargetBuy$46.00 ➝ $42.00Medium
i
3/23/2020UBS GroupReiterated RatingBuyMedium
i
3/19/2020DZ BankReiterated RatingBuyMedium
i
3/3/2020BarclaysReiterated RatingBuyLow
i
2/25/2020DZ BankReiterated RatingBuyMedium
i
2/21/2020CfraUpgradeHold ➝ Buy$38.00 ➝ $46.00Low
i
1/21/2020Jefferies Financial GroupUpgradeHold ➝ Buy$44.50Low
i
12/6/2019Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
i
10/30/2019DZ BankReiterated RatingNeutralLow
i
10/23/2019Redburn PartnersReiterated RatingBuy ➝ NeutralLow
i
8/29/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
8/19/2019Royal Bank of CanadaReiterated RatingNeutralLow
i
8/1/2019BTIG ResearchDowngradeBuy ➝ NeutralLow
i
7/30/2019DZ BankReiterated RatingNeutralLow
i
7/11/2019DZ BankReiterated RatingNeutralLow
i
6/20/2019BarclaysUpgradeEqual Weight ➝ Overweight$40.23Low
i
6/6/2019Royal Bank of CanadaReiterated RatingNeutralLow
i
5/9/2019Commerzbank AG (CBK.F)Reiterated RatingHold$54.00Low
i
5/7/2019DZ BankReiterated RatingNeutralLow
i
3/18/2019Royal Bank of CanadaReiterated RatingNeutralLow
i
3/5/2019DZ BankReiterated RatingNeutralLow
i
2/21/2019SunTrust BanksBoost Price TargetBuy ➝ Positive$48.00Low
i
12/10/2018Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
i
12/7/2018DZ BankReiterated RatingNeutralLow
i
11/20/2018SunTrust BanksLower Price TargetBuy$46.00Medium
i
10/26/2018UBS GroupUpgradeNeutral ➝ Buy$82.00High
i
Rating by Ian Douglas at UBS Group AG
10/17/2018DZ BankReiterated RatingBuy ➝ NeutralMedium
i
10/17/2018Royal Bank of CanadaReiterated RatingNeutralHigh
i
8/28/2018HSBCUpgradeHold ➝ BuyLow
i
8/17/2018Royal Bank of CanadaReiterated RatingNeutralLow
i
8/6/2018DZ BankReiterated RatingBuyLow
i
7/31/2018Royal Bank of CanadaReiterated RatingNeutralMedium
i
7/9/2018Bank of AmericaInitiated CoverageBuyLow
i
7/5/2018Credit Suisse GroupDowngradeOutperform ➝ NeutralLow
i
5/29/2018Royal Bank of CanadaReiterated RatingNeutralMedium
i
5/3/2018Royal Bank of CanadaReiterated RatingNeutralLow
i
4/24/2018Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyLow
i
4/23/2018DZ BankReiterated RatingBuyHigh
i
4/5/2018DZ BankReiterated RatingBuyLow
i
2/28/2018DZ BankReiterated RatingBuyMedium
i
2/27/2018Royal Bank of CanadaReiterated RatingNeutralHigh
i
1/4/2018UBS GroupUpgradeSell ➝ NeutralLow
i
1/2/2018Nord/LBReiterated RatingBuyLow
i
12/27/2017Nord/LBReiterated RatingBuyLow
i
12/21/2017SunTrust BanksSet Price TargetBuy$62.00Low
i
Rating by David S Macdonald at SunTrust Banks, Inc.
12/18/2017DZ BankReiterated RatingBuyLow
i
12/11/2017Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
i
11/13/2017DZ BankReiterated RatingBuyN/A
i
9/13/2017Royal Bank of CanadaReiterated RatingHold$44.00Low
i
8/8/2017Royal Bank of CanadaReiterated RatingNeutral$44.00Low
i
8/7/2017DZ BankReiterated RatingBuyMedium
i
8/1/2017Royal Bank of CanadaReiterated RatingNeutralLow
i
7/5/2017Royal Bank of CanadaReiterated RatingHold$44.00Low
i
7/4/2017UBS GroupReiterated RatingSellN/A
i
Rating by Ian Douglas at UBS Group AG
6/28/2017Nord/LBReiterated RatingBuyLow
i
5/30/2017Royal Bank of CanadaReiterated RatingHold$44.00High
i
5/29/2017DZ BankReiterated RatingNeutralLow
i
5/20/2017DZ BankReiterated RatingNeutralLow
i
5/11/2017DZ BankReiterated RatingNeutralLow
i
5/3/2017Royal Bank of CanadaReiterated RatingNeutralMedium
i
3/21/2017UBS GroupDowngradeBuy ➝ SellN/A
i
3/12/2017Sanford C. BernsteinReiterated RatingBuyLow
i
Rating by Lisa Bedell Clive at Sanford C. Bernstein
3/7/2017DZ BankReiterated RatingBuyN/A
i
2/24/2017Societe GeneraleDowngradeBuy ➝ HoldN/A
i
1/9/2017DZ BankReiterated RatingNeutralN/A
i
12/14/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
11/17/2016DZ BankReiterated RatingBuyN/A
i
11/10/2016DZ BankReiterated RatingNeutralN/A
i
11/1/2016Royal Bank of CanadaReiterated RatingSector Perform$41.00 ➝ $44.00N/A
i
11/1/2016Royal Bank of CanadaBoost Price TargetSector Perform$41.00 ➝ $44.00N/A
i
Rating by Frank Morgan at Royal Bank of Canada
10/18/2016CitigroupReiterated RatingBuyN/A
i
10/13/2016SunTrust BanksSet Price TargetBuy$48.00N/A
i
Rating by David S Macdonald at SunTrust Banks, Inc.
9/21/2016The Goldman Sachs GroupReiterated RatingBuyN/A
i
9/16/2016DZ BankReiterated RatingNeutralN/A
i
9/13/2016The Goldman Sachs GroupReiterated RatingBuyN/A
i
9/6/2016CitigroupUpgradeNeutral ➝ BuyN/A
i
8/9/2016Berenberg BankReiterated RatingBuyN/A
i
Rating by Upgraded, 3 days ago Buy at Berenberg Bank
8/4/2016DZ BankReiterated RatingNeutralN/A
i
7/8/2016Jefferies Financial GroupUpgradeUnderperform ➝ HoldN/A
i
5/24/2016Royal Bank of CanadaReiterated RatingHoldN/A
i
5/16/2016Robert W. BairdReiterated RatingHoldN/A
i
Rating by Whit Mayo at Robert W. Baird
5/10/2016DZ BankReiterated RatingSellN/A
i
4/11/2016Sanford C. BernsteinInitiated CoverageOutperformN/A
i
3/17/2016Nomura SecuritiesInitiated CoverageBuyN/A
i
3/4/2016DZ BankReiterated RatingSellN/A
i
2/13/2016Berenberg BankUpgradeBuyN/A
i
Rating by Upgraded, 2 days ago Buy at Berenberg Bank
1/26/2016Nord/LBReiterated RatingBuyN/A
i
1/26/2016UBS GroupReiterated RatingBuyN/A
i
1/5/2016UBS GroupUpgradeNeutral ➝ BuyN/A
i
1/4/2016JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/A
i
(Data available from 12/3/2015 forward)
Fresenius Medical Care AG & Co. KGaA logo
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides pharmacy services, vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2019, it operated 3,994 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Read More

Today's Range

Now: $41.61
$41.58
$41.98

50 Day Range

MA: $41.49
$38.10
$43.54

52 Week Range

Now: $41.61
$29.17
$46.55

Volume

95,075 shs

Average Volume

279,105 shs

Market Capitalization

$24.37 billion

P/E Ratio

16.51

Dividend Yield

1.19%

Beta

1.24